Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611452 | 0.77 | PTGS2 (0.43) | PTGS2CA1CA2CA9CA12 | |
| SCHEMBL16611316 | 0.76 | CA1 (0.42) | PTGS2CA1CA2CA9CA12 | |
| SCHEMBL16611691 | 0.76 | PTGS2 (0.36) | PTGS2CA1CA2CA9CA12 | |
| SCHEMBL16610935 | 0.74 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL16610829 | 0.67 | CCNA2 (0.47) | PTGS2CA1CA2CA9CA12 | |
| SCHEMBL16611625 | 0.66 | CCNA2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL16611260 | 0.65 | PTGS2 (0.42) | PTGS2CA1CA2CA9CA12 | |
| SCHEMBL6013909 | 0.65 | PTGS2 (0.93) | PTGS2CA1CA2CA9CA12 | |
| SCHEMBL6352330 | 0.62 | PTGS2 (1.00) | PTGS2CA1CA2CA9CA12 | |
| SCHEMBL5201734 | 0.62 | PTGS2 (0.66) | PTGS2CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | PTGS2 550/4885CA1 2704/4885CA2 1618/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | PTGS2 550/4885CA1 2704/4885CA2 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.